Hyperthyroidism in cats: transdermal methimazole (pluronic lecithin gel) vs oral methimazole — POSSIBLE

In cats with hyperthyroidism, how does transdermal methimazole in a pluronic lecithin organogel (PLO) compare with oral methimazole for thyroid (T4) control and gastrointestinal adverse effects?

Shelf #233 · gate-verified and approved by the developer

POSSIBLE: Transdermal PLO methimazole controls thyroid hormone, but more slowly than oral methimazole, and with fewer gastrointestinal adverse effects. In the one randomised head-to-head trial (Sartor 2004, 47 newly diagnosed cats, 2.5 mg q12h by either route), significantly more oral cats had serum T4 within the reference range at 2 weeks (14 of 16) than transdermal cats (14 of 25; P = .027); by 4 weeks the difference was no longer significant (9 of 11 oral vs 14 of 21 transdermal), on much-reduced numbers. Gastrointestinal adverse effects were more frequent on oral treatment (4 of 17 cats) than transdermal (1 of 27; P = .04), with no differences in neutropenia, hepatotoxicity or facial excoriations. A second prospective comparison using a different, lipophilic transdermal formulation against oral carbimazole (Hill 2011) detected no differences over 12 weeks, and a single-arm prospective PLO study (Lécuyer 2006) confirms the gel itself lowers T4 substantially within 28 days. Gaps: only one randomised trial tests the actual PLO gel against oral methimazole, it ran just 4 weeks with attrition by week 4, no carded record states blinding, and compounded-gel variability between pharmacies is not addressed by any carded record. Drafted Nov 10, 2026 (VetMed build, topic #233); all figures from abstracts fetched and verified at drafting.

Sartor 2004: oral methimazole normalised T4 faster at 2 weeks, but transdermal PLO caused fewer GI adverse effects (1 of 27 vs 4 of 17)

Randomized study (record's own wording: cats 'were randomized'); publication type: Research Support, Non-U.S. Gov't — no blinding stated in the record

Who: Cats: 47 cats with newly diagnosed hyperthyroidism in a clinical setting, randomized to receive either transdermal methimazole in pluronic lecithin organogel (PLO; applied to the inner pinna) or oral methimazole (2.5 mg q12h for either route), evaluated at weeks 0, 2 and 4 with physical exam, body weight, CBC, biochemical panel, urinalysis, total T4, indirect Doppler blood pressure and an owner questionnaire; 44 cats followed the protocol (17 oral and 27 transdermal).

Result: Significantly more cats treated with oral methimazole had serum T4 concentrations within the reference range after 2 weeks (14 of 16 cats) compared with those treated by the transdermal route (14 of 25; P = .027). This difference was no longer significant by 4 weeks of treatment (9 of 11 for oral versus 14 of 21 for transdermal), possibly because of inadequate numbers evaluated by 4 weeks. Cats treated with oral methimazole had a higher incidence of gastrointestinal (GI) adverse effects (4 of 17 cats) compared with cats treated with transdermal methimazole (1 of 27; P = .04), but no differences were found between groups in the incidence of neutropenia, hepatotoxicity, or facial excoriations.

Watch out: The record does not state blinding, and none is claimed here. Numbers evaluated shrank considerably by week 4, which the authors themselves offer as the reason the week-2 T4 difference lost significance. Follow-up was only 4 weeks, so longer-term control, dose escalation and rare adverse effects are outside this trial.

Sartor LL, Trepanier LA, Kroll MM, Rodan I, Challoner L. Efficacy and safety of transdermal methimazole in the treatment of cats with hyperthyroidism. Journal of veterinary internal medicine. 2004;18(5):651-5. PMID: 15515580. Registry ID: none in the record. MeSH: Administration, Cutaneous · Administration, Oral · Animals · Antithyroid Agents/adverse effects · Antithyroid Agents/therapeutic use · Cat Diseases/drug therapy · Cats · Gels · Hyperthyroidism/drug therapy · Hyperthyroidism/veterinary · Methimazole/adverse effects · Methimazole/therapeutic use · Radioimmunoassay/veterinary · Reaction Time · Safety · Treatment Outcome

Hill 2011: once-daily transdermal methimazole in a novel lipophilic vehicle matched twice-daily oral carbimazole over 12 weeks, with no significant differences detected

Prospective study (record's own wording); publication type: Research Support, Non-U.S. Gov't — allocation method and blinding not stated in the record

Who: Cats: 45 client-owned cats with newly diagnosed, untreated hyperthyroidism, treated prospectively with carbimazole (5 mg p.o., q12h) or methimazole (10 mg) applied to the inner pinnae q24h, and examined after 0, 1, 4, 8 and 12 weeks of treatment, with clinical signs, body weight, systolic blood pressure, hematologic, serum biochemical and urine parameters, total serum thyroxine (TT4) and serum methimazole concentrations recorded (per-group numbers are not given in the record).

Result: No significant differences between groups were detected at day 0. Both formulations were effective in treating hyperthyroidism. No significant differences were detected in thyroxine concentrations, body weight, blood pressure, heart rate, alkaline phosphatase, alanine aminotransferase, creatinine, urea, and urine specific gravity (USG) between groups. The serum methimazole concentrations correlated poorly with TT4 concentrations in both groups. The authors concluded that once-daily application of the novel transdermal formulation was as effective and safe as twice-daily oral carbimazole over this 12-week trial.

Watch out: This is not the PLO gel of the shelf question: the vehicle was a novel lipophilic formulation, and the oral comparator was carbimazole (converted to methimazole in the body), not oral methimazole tablets. The record does not state randomisation or blinding, and 'no significant differences detected' in 45 cats is not a formal equivalence demonstration — it supports the transdermal route generally, not the PLO gel specifically.

Hill KE, Gieseg MA, Kingsbury D, Lopez-Villalobos N, Bridges J, Chambers P. The efficacy and safety of a novel lipophilic formulation of methimazole for the once daily transdermal treatment of cats with hyperthyroidism. Journal of veterinary internal medicine. 2011;25(6):1357-65. PMID: 22092628. Registry ID: none in the record. MeSH: Administration, Cutaneous · Animals · Antithyroid Agents/administration & dosage · Antithyroid Agents/blood · Antithyroid Agents/chemistry · Antithyroid Agents/therapeutic use · Carbimazole/administration & dosage · Carbimazole/therapeutic use · Cat Diseases/drug therapy · Cats · Chromatography, High Pressure Liquid · Dosage Forms · Hyperthyroidism/drug therapy · Hyperthyroidism/veterinary · Methimazole/administration & dosage · Methimazole/blood · Methimazole/chemistry · Methimazole/therapeutic use · Thyroxine/blood

Lécuyer 2006: transdermal methimazole 5 mg q12h lowered mean T4 from 97.31 to 14.63 nmol/L by day 28 in newly diagnosed hyperthyroid cats

Prospective clinical study, single-arm (record's own wording); publication type: Research Support, Non-U.S. Gov't

Who: Cats: 13 cats newly diagnosed with hyperthyroidism at a university hospital, all treated with a transdermal formulation of methimazole at 5 mg (0.1 mL; concentration 50 mg/mL) applied to the internal ear pinna every 12 h for 28 days, with physical examination, complete blood cell count, serum biochemical analysis and serum T4 at day 0, day 14 and day 28; 10 cats completed the study.

Result: Clinical improvement, as well as a significant decrease in T4, was noted in all cats that completed the study. Serum T4 at day 14 and day 28 was significantly lower, at 27.44 nmol/L (s = 37.51) and 14.63 nmol/L (s = 10.65) respectively (P < 0.0001), compared with day 0 (97.31 nmol/L, s = 37.55). Only 1 cat showed a cutaneous adverse reaction, along with a marked thrombocytopenia.

Watch out: Single-arm: there is no oral-methimazole comparator in this study, so it shows the transdermal route can lower T4, not how it compares with tablets. The record's abstract does not name the gel vehicle, so this card supports transdermal methimazole at this dose rather than PLO specifically. Three of 13 cats did not complete the study, and the one serious adverse event (marked thrombocytopenia with a cutaneous reaction) occurred on the transdermal route.

Lécuyer M, Prini S, Dunn ME, Doucet MY. Clinical efficacy and safety of transdermal methimazole in the treatment of feline hyperthyroidism. The Canadian veterinary journal. 2006;47(2):131-5. PMID: 16579038. Registry ID: none in the record. MeSH: Administration, Cutaneous · Animals · Antithyroid Agents/therapeutic use · Blood Cell Count/veterinary · Blood Chemical Analysis/veterinary · Cat Diseases/drug therapy · Cats · Female · Hyperthyroidism/drug therapy · Hyperthyroidism/veterinary · Male · Methimazole/therapeutic use · Prospective Studies · Safety · Thyroxine/blood · Treatment Outcome

Synthesis: transdermal methimazole works and is gentler on the gut, but oral methimazole restores T4 to the reference range faster

Synthesis

Who: Synthesis of the cards above: Sartor 2004 (47 newly diagnosed hyperthyroid cats, randomized, transdermal PLO vs oral methimazole 2.5 mg q12h, 4 weeks), Hill 2011 (45 client-owned cats, prospective, lipophilic transdermal methimazole vs oral carbimazole, 12 weeks) and Lécuyer 2006 (13 newly diagnosed cats, prospective single-arm transdermal methimazole 5 mg q12h, 28 days).

Result: (1) Speed of control favours oral: at 2 weeks, 14 of 16 oral cats versus 14 of 25 transdermal cats had T4 in the reference range (P = .027), with no significant difference by week 4 on reduced numbers (Sartor). (2) GI tolerability favours transdermal: 1 of 27 transdermal cats versus 4 of 17 oral cats had GI adverse effects (P = .04), with no difference in neutropenia, hepatotoxicity or facial excoriations (Sartor). (3) The transdermal route itself is genuinely effective: mean T4 fell from 97.31 to 14.63 nmol/L over 28 days on gel alone (Lécuyer), and a lipophilic transdermal formulation detected no differences against oral carbimazole over 12 weeks (Hill).

Watch out: Only Sartor 2004 compares the actual PLO gel with oral methimazole, and only for 4 weeks; Hill's vehicle and comparator drug both differ from the shelf question, and Lécuyer has no comparator at all. No carded record states blinding, and none addresses variability between compounded PLO preparations or control beyond 12 weeks.

Synthesis of Sartor LL et al. PMID: 15515580; Hill KE et al. PMID: 22092628; Lécuyer M et al. PMID: 16579038. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.